

Contact: **Rx³ Pharmaceuticals**
John P. Schmid
Chief Financial Officer
(858) 452-0370, x. 105
jschmid@rx3pharma.com

Rx³ Pharmaceuticals Expands Board and Management Team

Anti-infective company hires VC as Executive Chairman of the Board

San Diego, CA, June 27, 2005 – Rx³ Pharmaceuticals, Inc., an anti-infective drug discovery company, announced today that it has hired Jeffrey Stein, Ph.D. to serve as its Chairman of the Board in an executive capacity. He will focus his efforts on business development and science strategy. Dr. Stein is taking on this position in conjunction with his recent acceptance into the Kaufman Fellowship program, where he will be working as a Venture Partner with Sofinnova Venture Capital. He was previously founder and Chief Scientific Officer of Quorex Pharmaceuticals, which was acquired by Pfizer. Dr. Stein has served as a scientific adviser to Rx³ since early 2005 and he will also become Chairman of the Company’s Scientific Advisory Board as part of this appointment.

“We are excited to have Jeff join our management team and advance the Company’s future development,” said Dr. John Finn, President of Rx³ Pharmaceuticals. “Jeff is a proven leader and innovator in using structure based drug design to create innovative antibacterial drugs. He brings a wealth of knowledge, experience, and relationships to this role, and we are pleased that he is willing to make time to work with us as a colleague.”

Jeff Stein said, “Rx³ is the type of company that can be successful in this challenging biotech environment and I welcome the opportunity to participate as part of the management team. With its rapidly evolving programs, high quality team, and attractive market opportunity, that will enable this biotech company to be successful.”

About Rx³ Pharmaceuticals, Inc.

Rx³ Pharmaceuticals, Inc. is a drug discovery company applying its structure-based drug design technologies to four antimicrobial programs. These programs target novel proteins in validated pathways. Rx³’s discovery team has advanced anti-bacterial programs into later stage drug discovery and expects to identify development candidates from them. For more information, visit www.rx3pharma.com.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements and are subject to risks and uncertainties that may cause actual results to differ materially from the results described in, or implied by, the forward-looking statements. Rx³ disclaims any intent or obligation to update these forward-looking statements.

###

